177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy

Cancer

Volumn 116, Issue SUPPL. 4, 2010, Pages 1084-1092

  Garkavij, Michael ^a   Nickel, Mattias ^a   Sjögreen Gleisner, Katarina ^a   Ljungberg, Michael ^a   Ohlsson, Tomas ^a   Wingårdh, Karin ^a   Strand, Sven Erik ^a   Tennvall, Jan ^b  

^a LUND UNIVERSITY   (Sweden)

^b NONE

Author keywords

Carcinoid; Dosimetry; Fractionation; Imaging; Lu 177; Neuroendocrine tumors; Octreotate; Radionuclide therapy; SPECT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTATE LU 177; ANTINEOPLASTIC AGENT; PENTETIC ACID; PENTETIC ACID OCTREOTIDE IN 111; PENTETREOTIDE IN 111; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; VAMIN; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; DRUG DERIVATIVE; LUTETIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL PAIN; ADULT; AGED; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOSIMETRY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; KIDNEY; KIDNEY MASS; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTOPENIA; TREATMENT PLANNING; TUMOR LOCALIZATION; VOMITING; ARTICLE; COMPARATIVE STUDY; FORECASTING; METASTASIS; METHODOLOGY; PATHOLOGY; RADIOMETRY;

FORECASTING; HUMANS; LUTETIUM; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE;

EID: 76249124603     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24796     Document Type: Conference Paper

References (20)

1. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133-140.
2. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282.
3. Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with Y-DOTA,Tyr-octreotide and Lu-DOTA-Tyr-octreotate. J Nucl Med. 2005;46(suppl 1):83S-91S.
4. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.
5. Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys. 1995;31:1249-1256.
6. Konijnenberg M, Melis M, Valkema R, Krenning E, de Jong M. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med. 2007;48:134-142.
7. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28:1319-1325.
8. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9-15.
9. Sjogreen K, Minarik D, Ljungberg M. The LundADose method for activity quantification and absorbed dose assessment in radionuclide therapy. Cancer Biother Radiopharm. 2005;20:92-97.
10. Sjogreen K, Ljungberg M, Strand SE. An activity quantification method based on registration of CT and whole-body scintillation camera images, with application to 131I. J Nucl Med. 2002;43:972-982.
11. Minarik D, Sjogreen K, Ljungberg M. A new method to obtain transmission images for planar whole-body activity quantification. Cancer Biother Radiopharm. 2005;20:72-76.
12. Sjogreen K, Ljungberg M, Wingardh K, Erlandsson K, Strand SE. Registration of emission and transmission whole-body scintillation camera images J Nucl Med. 2001;42: 1563-1570.
13. Ljungberg M, Strand SE. A Monte Carlo program simulating scintillation camera imaging. Comp Meth Progr Biomed. 1989;29:257-272.
14. Frey EC, Tsui BMW. A New Method for Modeling the Spatially-Variant, Object-Dependent Scatter Response Function in SPECT: Conference Records of the IEEE Medical Imaging Conference; 1996; Anaheim, CA; 1082-1082.
15. Berger MJ, Hubbell JR. XCOM: Photon cross-sections on a personal computer. Washington, DC: National Bureau of Standards; 1987; NBS IR 87-3597.
16. Loevinger R, Berman M. A revised schema for calculation of the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet No. 1, Revised. New York: Society of Nuclear Medicine; 1976.
17. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J of Nucl Med. 2005; 46:1023-1027.
18. International Commission on Radiological. Basic anatomical and physiological data for use in radiological protection. 2003. ICRP Publication 89.
19. Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm. 2005;20:47-51.
20. Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847-1856.